Applied Therapeutics (APLT) Cash & Equivalents (2023 - 2025)
Historic Cash & Equivalents for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to $11.9 million.
- Applied Therapeutics' Cash & Equivalents fell 8792.21% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year decrease of 8792.21%. This contributed to the annual value of $79.4 million for FY2024, which is 5912.06% up from last year.
- As of Q3 2025, Applied Therapeutics' Cash & Equivalents stood at $11.9 million, which was down 8792.21% from $30.4 million recorded in Q2 2025.
- In the past 5 years, Applied Therapeutics' Cash & Equivalents registered a high of $146.5 million during Q1 2024, and its lowest value of $11.9 million during Q3 2025.
- Moreover, its 3-year median value for Cash & Equivalents was $49.9 million (2023), whereas its average is $62.4 million.
- Per our database at Business Quant, Applied Therapeutics' Cash & Equivalents skyrocketed by 53926.34% in 2024 and then crashed by 8792.21% in 2025.
- Over the past 3 years, Applied Therapeutics' Cash & Equivalents (Quarter) stood at $49.9 million in 2023, then skyrocketed by 59.12% to $79.4 million in 2024, then tumbled by 84.96% to $11.9 million in 2025.
- Its Cash & Equivalents stands at $11.9 million for Q3 2025, versus $30.4 million for Q2 2025 and $50.8 million for Q1 2025.